

HealthDiagnostic

Equol

Labmaster Equol TR-FIA

Quantitative time-resolved fluoroimmunoassay

The Researcher's new Tool for Studies of Anti-Carcinogenic Potency of Isoflavonoids

Equol is a metabolite produced by intestinal bacteria from the isoflavone Daidzein, which occurs in soy beans⁽¹⁻³⁾. Recently it was shown that high excretion of Equol is associated with a significant reduction in breast cancer risk⁽⁴⁾. Equol showed to have a higher anti-carcinogenic potency, in vitro and in vivo, than Daidzein itself⁽⁵⁻⁹⁾. These findings make Equol a strong candidate for a natural cancer-protective compound.

The TR-FIA method for plasma Equol provides a new procedure for the assay of Equol for large screening studies.

The method is reliable, practical, sensitive and specific for Equol. Crossreaction does not influence the results.




Equol TR-FIA

WHAT IS EQUOL?

Background

Isoflavonoids are a group of diphenolic hormone-like compounds of dietary origin that are of great interest particularly because of their anti-carcinogenic potency, but also because of their association with other Western diseases like coronary heart disease (10-12). The isoflavonoids occur mainly in soybean products and clover seeds and leaves (13-15). When consumed, isoflavonoids are converted by the intestinal microflora to biologically active secondary plant metabolites. Ingested glycosides are rapidly hydrolyzed by the gut bacteria, whereafter the aglycones undergo further metabolism. In this way the aglycone daidzein, which is formed from formononetin, is reduced by the intestinal microflora to the **isoflavan equol** (about 70%) and *O*-desmethylangolensin (about 5-20%) (1,2,3,16,17).



Equol was identified in human urine for the first time in 1982 (18,19). Recently it was shown that equol has higher anti-carcinogenic potency, both *in vitro* and *in vivo*, than daidzein itself.

REFERENCES:

1. Heinonen S., Wähälä K. and Adlercreutz H., *Anal Biochem* **274** (1999) 211-219.
2. Shutt D.A., Weston R.H. and Hogan J.P., *Austr J Agric Res* **21** (1970) 713-722.
3. Adlercreutz H. *Front gastrointest Res* 1988; **14**: 165-176.
4. Ingram D., Sanders K., Kolybaba M. and Lopez D., *Lancet* **350** (1997) 990-994.
5. Sathyamoorthy N. and Wang T.T.Y., *Eur J Cancer* **33** (1997) 2384-2389.
6. Rowland I, Wiseman H, Sanders T, et al. *Biochemical Society Transactions* 1999; **27**:304-308.
7. Markiewicz L., Garey J., Adlercreutz H. and Gurdipe E., *J Steroid Biochem Molec Biol* **45** (1993) 399-405.
8. Hodgson J.M., Croft K.D., Puddey I.B., Mori T.A. and Beilin L.J., *J Nutr Biochem* **7** (1996) 664-669.
9. Arora A, Nair MG, Strassburg GM, *Arch. Biochem. Biophys.* 1998; **356**:133-141.
10. Adlercreutz H. and Mazur W., *Phyto-oestrogens and Western diseases. Ann Med* **29** (1997) 95-120.
11. Vanharanta M., Vuolilainen S., Lakka T.A., van der Lee M., Adlercreutz H. and Salonen J.T., *Lancet* **354** (1999) 2112-2115.
12. Adlercreutz H., *Phyto-oestrogens and cancer. Lancet Oncology* 2002; **3**: 364-373
13. Bradbury R.B. and White D.E. (Edited by Haaris R.S., Marrian G.F., and Thimann K.V.). Academic Press Inc., New York (1954) pp. 207-233.
14. Eldridge A. and Kwolek W. F., *Journal of Agriculture and Food Chemistry* **31** (1983) 394-396.
15. Price K.R. and Fenwick G.R., *Naturally occurring oestrogens in foods - A review. Food Add Contam* **2** (1985) 73-106.
16. Setchell K.D.R. and Adlercreutz H.: (Edited by Rowland I.), Academic Press, London (1988) pp. 315-345.
17. Kelly G.E., Nelson C., Waring M.A., Joannou G.E. and Reeder A. Y., *Clin Chim Acta* **223** (1993) 9 - 22.
18. Axelson M., Kirk D.N., Farrant R.D., Cooley G., Lawson A.M. and Setchell K.D.R., *Biochemical Journal* **201** (1982) 353-357.
19. Adlercreutz H., Fotsis T., Heikkinen R., Dwyer J. T., Woods M., Goldin B.R. and Gorbach S.L. *Lancet* **2** (1982) 1295-1299.


PERFORMANCE CHARACTERISTICS

Specificity of Equol Antiserum Precision


Compound	% cross-reactivity
Equol	100.0
6-OH-daidzein	0.0
Genistein	0.0
8-OH-daidzein	0.0
O-desmethylangolensin	0.0
Daidzein	0.8
5-OH-equol	14.0
Dihydrogenistein	12.0
Dihydrodaidzein	4.0
Cis-4-OH-equol	10.7
Dehydroequol	42.3
Trans-4-OH-equol	35.0
4'-O-methylequol	275.0

Intra- and interassay CVs for plasma and urine equol by TR-FIA			
Sample	Concentration (nmol/l)	Intra-assay CV (%)	Inter-assay CV (%)
Plasma method			
Low	4.5	6.5 (n=10)	9.7 (n=10)
Medium	52.6	5.5 (n=10)	6.0 (n=10)
High	133.7	6.3 (n=10)	5.4 (n=10)
Urine method			
Low	203.9	6.9 (n=10)	7.7 (n=10)
Medium	1663.5	3.4 (n=10)	7.4 (n=10)
High	6143.9	3.9 (n=10)	7.6 (n=10)

Correlation between plasma TR-FIA and GC-MS




Standard Curve of plasma Equol for TR-FIA (ten assays at different times)



THE METHOD


COMPETITIVE IMMUNOASSAY

- A sample preparation by hydrolyze and ether extraction




- 90 minutes incubation

- Aspiration and washing



- 5 minutes incubation



- Fluorescence measurement

ORDERING INFORMATION

Labmaster Equol TR-FIA

- Cat. no.: 1212-2002
- Includes:
 - microtitration plate (96 wells)
 - reagents for testing standards and samples
 - instructions for use



Labmaster Ltd.
Fiskarsinkatu 11,
FIN-20750 Turku, Finland
Tel. +358-2-276 0555
Fax: +358-2-2760550
www.labmaster.fi